Eli Lilly’s Taltz has followed Novartis rival Cosentyx into all the diseases it treats. But this time, Lilly wants to be first. Monday, the Indianapolis drugmaker trumpeted phase 3 data showing its IL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback